| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.08. | Klaria Pharma Holding AB: Klaria Receives EU Notification of Allowance for Sumatriptan Alginate Film | 505 | GlobeNewswire (Europe) | Klaria has received a Notice of Allowance from the European Patent Office for the second patent in the Sumatriptan Alginate Film (SAF) patent portfolio. The Notice of Allowance indicates that the second... ► Artikel lesen | |
| 26.06. | Klaria Pharma Holding AB: Report from the Annual General Meeting of Klaria Pharma Holding AB (publ) | 371 | GlobeNewswire (Europe) | Today, the Annual General Meeting 2026 of Klaria Pharma Holding AB (publ), reg. no. 556959-2917, was held. Below is a summary of the resolutions adopted by the Annual General Meeting (all in accordance... ► Artikel lesen | |
| 05.06. | KLARIA PHARMA HOLDING AB: Klaria Annual Report 2025 | 1 | Cision News | ||
| 05.06. | Klaria Pharma Holding AB: Klaria receives 25 MSEK in loan financing with the possibility of an additional 15 MSEK | 198 | GlobeNewswire (Europe) | Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that Klaria has entered into an agreement for a bridge loan of 25 MSEK from a Swedish finance company. The agreement also includes... ► Artikel lesen | |
| 29.05. | Klaria Pharma Holding AB: Klaria Interim Report Q1 2026 | 212 | GlobeNewswire (Europe) | Klaria Interim Report Q1 2026 1 January - 31 March
Summary of the interim reportFirst quarter of 2026 The group in total - Net sales 0.1 MSEK (9.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D... ► Artikel lesen | |
| 28.05. | KLARIA PHARMA HOLDING AB: Klaria adjusts annual report release date | 1 | Cision News | ||
| 25.05. | Klaria Pharma Holding AB: Summons to the Annual General Meeting of Klaria Pharma Holding AB (publ) | 356 | GlobeNewswire (Europe) | With a change from what has been previously announced, the shareholders of Klaria Pharma Holding AB (publ), corporate registration number 556959-2917, are hereby invited to attend the Annual General... ► Artikel lesen | |
| 22.05. | KLARIA PHARMA HOLDING AB: Klaria postpones interim Q1 report | 1 | Cision News | ||
| KLARIA PHARMA Aktie jetzt für 0€ handeln | |||||
| 21.05. | KLARIA PHARMA HOLDING AB: Klaria postpones publication of the annual report | 2 | Cision News | ||
| 23.04. | Notice of the Annual General Meeting of Klaria Pharma Holding AB (publ) | 1 | Cision News | ||
| 05.04. | KLARIA PHARMA HOLDING AB: Annula Genernal Meeting Date Change: Klaria Pharma Holding (publ) | 2 | Cision News | ||
| 19.03. | Correction: Incorrect inclusion of MAR text in earlier release.Summary of extraordinary general meeting in Klaria Pharma Holding AB (publ) | 1 | Cision News | ||
| 19.03. | Klaria Pharma Holding AB: Summary of extraordinary general meeting in Klaria Pharma Holding AB (publ) | 372 | GlobeNewswire (Europe) | Today, an extraordinary general meeting was held in Klaria Pharma Holding AB (publ), company registration number 556959-2917. Below is a summary of the resolutions adopted by the extra general meeting... ► Artikel lesen | |
| 02.03. | Klaria Pharma Holding AB (publ) Summons to Extraordinary General Meeting | 2 | Cision News | ||
| 20.02. | Klaria Pharma Holding AB: Klaria Year-End Report | 757 | GlobeNewswire (Europe) | Klaria Year-End Report Q4 2025
1 January-31 December 2025
SummaryFourth quarter of 2025 The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses for... ► Artikel lesen | |
| 23.12.25 | Klaria Pharma Holding AB: Klaria accelerates its business development work in collaboration with BDO | 919 | GlobeNewswire (Europe) | With Klaria's product, Sumatriptan Alginate Film, approved in the EU and set to launch in 2026 in the largest EU markets, the company has now engaged BDO LLP's UK Life Sciences & Healthcare M&A team... ► Artikel lesen | |
| 17.12.25 | Klaria Pharma Holding AB: Klaria Receives Positive Opinion on Sumatriptan Oral Film Patent Application | 245 | GlobeNewswire (Europe) | Klaria announced earlier in the year that it had submitted an additional patent application on the sumatriptan oral film product to further protect the product and potentially extend its market exclusivity.... ► Artikel lesen | |
| 26.11.25 | Klaria Pharma Holding AB: Klaria Interim Report Q3 2025 | 270 | GlobeNewswire (Europe) | Klaria Interim Report
1 July - 30 September 2025
Summary of the interim reportThird quarter of 2025
The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D... ► Artikel lesen | |
| 28.08.25 | Klaria Pharma Holding AB: Klaria Interim Report Q2 2025 | 389 | GlobeNewswire (Europe) | Klaria interim report
1 April-30 June 2025
Summary of the interim reportSecond quarter of 2025 The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB | 57,51 | +0,19 % | Schlafender Biotech-Riese vor der nächsten Wachstumsphase? BioNTech, Emyria und die neue Macht der Datenplattformen | ||
| DERMAPHARM | 40,150 | +0,63 % | DERMAPHARM lieferte solide Halbjahreszahlen | Der Umsatz stieg im ersten Halbjahr 2026 um 2,9 % auf 591,0 Mio. €, das bereinigte EBITDA um 10,3 % auf 163,2 Mio. €. Positiv stach die Margenverbesserung um 1,8 Prozentpunkte auf 27,6 % hervor. Rückenwind... ► Artikel lesen | |
| INCYTE | 110,00 | +0,50 % | Incyte: H.C. Wainwright bekräftigt Rating nach Daten zu Krebsmedikament | ||
| GREEN THUMB INDUSTRIES | 6,490 | +0,46 % | Green Thumb Industries: Green Thumb Opens Its 24th Florida Location, RISE Dispensary Port St. Lucie, on August 22 | ||
| SELLAS LIFE SCIENCES | 13,050 | -1,51 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| COSMO | 61,90 | +0,32 % | Cosmo Pharmaceuticals N.V.: Cosmo Announces SIX Ticker Symbol Change to "CMHC" | Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - August 14, 2026) - Cosmo N.V. (SIX: COPN) (FSE: C43) ("Cosmo") today announced that it will change its ticker... ► Artikel lesen | |
| OPKO HEALTH | 1,280 | +0,79 % | OPKO Health Secures $125 Million Financing Against Mazdutide Royalties | ||
| OXFORD BIOMEDICA | 6,000 | +7,14 % | Broker tips: Rolls Royce, Oxford Biomedica | ||
| CITIUS PHARMACEUTICALS | 0,600 | -0,02 % | Citius Pharmaceuticals, Inc. - 8-K, Current Report | ||
| SUMITOMO PHARMA | 7,427 | -1,93 % | Sumitomo Pharma, Novo Nordisk Win Japan Nod For Wegovy In MASH | TOKYO (dpa-AFX) - Sumitomo Pharma Co., Ltd. (4506.T) announced on Friday that Japan has cleared Wegovy Subcutaneous Injection, which it co-promotes with Novo Nordisk B A/S (NVO), to treat metabolic... ► Artikel lesen | |
| VETOQUINOL | 69,60 | 0,00 % | Dividendenbekanntmachungen (03.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGEAS SA/NV BE0974264930 - 2,25 EUR AMKOR TECHNOLOGY INC US0316521006 0,0835 USD 0,0717 EUR AVERY DENNISON CORP US0536111091 1... ► Artikel lesen | |
| ASTRID INTELLIGENCE | 0,001 | 0,00 % | Astrid Intelligence - Corrective announcement - Directors' Dealing | ||
| BIOHARVEST SCIENCES | 1,570 | +0,64 % | BioHarvest Sciences Inc.: BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update | Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production program over two years for rare botanical fragrance, that BioHarvest expects to drive profitable growth... ► Artikel lesen | |
| OCUMENSION THERAPEUTICS | 0,555 | +4,72 % | NICOX SA: Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension | Press Release Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension
Ocumension has submitted the New Drug Application (NDA) to the Chinese National Medical Products Administration... ► Artikel lesen | |
| BAYER | 48,040 | -1,17 % | Bayer ist mehr als die Roundup-Wette | Bayer hat an der Börse lange fast nur über ein einziges Thema funktioniert: Glyphosat. Gute Pharmadaten, Agrarwachstum oder Sparprogramme wurden regelmäßig von neuen US-Rechtsrisiken überlagert. Im... ► Artikel lesen |